Skip to main content
delveinsight blog
  • ABOUT
    • About Us
    • Our Leadership
    • Our Clients
  • CAPABILITIES & SOLUTIONS
    • Reports
    • Competitive Intelligence
    • Case Study
  • CONSULTING SERVICE
  • REPORT STORE
  • MEDIA
    • Blog
    • Press Releases
    • White Papers / Newsletter
    • Events
  • CAREER
  • CONTACT US
  • Report Store

Month: November 2018

Nov 30 Scientists Now Target Attacking Evolution Process of Cancer Cells

Scientists Now Target Attacking Evolution Process of Cancer Cells

Nov 30, 2018Nov 30, 2018 DelveInsight Leave a comment

It is needless to mention that the tug-of-war between cancer and researchers has been growing stronger and stronger. On one side, cancer has positioned itself as…

Read More
Nov 29 The Business Cocktail

The Business Cocktail

Nov 29, 2018 DelveInsight Leave a comment

Prometic bags USD 50 Million stock sale option to ease a cash crunch Prometic Life Sciences got into an agreement for selling USD 50 million in stock. This…

Read More
Nov 28 Researchers say CRISPR edits to a human embryo worked

Researchers say CRISPR edits to a human embryo worked

Nov 28, 2018 DelveInsight Leave a comment

The researchers announced that they had edited human embryos to repair a damaged gene that can lead to heart failure, but critics raised their eyebrows. Now,…

Read More
Nov 26 Sleeping at Workplaces: Re-energizing Formula or OSA Disease?

Sleeping at Workplaces: Re-energizing Formula or OSA Disease?

Nov 26, 2018 DelveInsight Leave a comment

Do you often sleep during work? Well, if you do so, you might proudly claim yourself to be an efficient and hard worker as work stress…

Read More
Nov 23 Will Technology Eventually Render Chemotherapy as Redundant for Cancer Treatment? 

Will Technology Eventually Render Chemotherapy as Redundant for Cancer Treatment? 

Nov 23, 2018Nov 23, 2018 DelveInsight 1 Comment

It is needless to mention that Chemotherapy has been the most dependable cancer therapy. But, a new area of research shows the possibility of technology taking…

Read More
Nov 22 The Business Cocktail

The Business Cocktail

Nov 22, 2018 DelveInsight Leave a comment

Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become…

Read More
Nov 21 Newsletter

Newsletter

Nov 21, 2018Nov 21, 2018 DelveInsight Leave a comment
Read More
Nov 21 Snippet- The lab-grown mini brains generate electrical patterns

Snippet- The lab-grown mini brains generate electrical patterns

Nov 21, 2018 DelveInsight Leave a comment

The Mini brains grown in a dish have produced human-like brain waves. They are the electrical patterns look similar to those of premature babies. This would…

Read More
Nov 20 Notizia

Notizia

Nov 20, 2018 DelveInsight Leave a comment

Gene editing, a possible treatment, for inherited kidney disease Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or…

Read More
Nov 16 Actinic Keratosis – A Warning Sign for Potential Skin Cancer

Actinic Keratosis – A Warning Sign for Potential Skin Cancer

Nov 16, 2018 DelveInsight Leave a comment

Actinic keratosis (AK) is a chronic and prevalent disease affecting areas of sun-exposed skin where visible and subclinical, non-visible lesions coexist. AK lesions are being represented…

Read More

Posts navigation

1 2 3 Older posts

Recent Posts

  • Human cells reprogrammed to create insulin in diabetic mice
  • The Business cocktail
  • The antidepressant drug gets support from FDA
  • Notizia
  • Raynaud’s Disease -A debilitating condition

Browse by Category

  • Anti-coagulants (6)
  • API Business Opportunity (3)
  • Articles (182)
  • Atrial Fibrillation (3)
  • Business Consultant (224)
    • Pharma Consultant (208)
  • Chimeric Antigen Receptor (CAR) T-cell Therapy (3)
  • CNS Indications (1)
  • CVS Indications (4)
  • DelveInsight's Drug Report (22)
  • DelveInsight's Indication Pipeline Reports (8)
  • DelveInsight's Oncology based Reports (14)
  • Gene Therapy Products (29)
  • Infographics (11)
  • new therapeutic target (2)
  • Newsletter (2)
  • Notizia (98)
  • Oncology based Indications (7)
  • Orphan market (3)
  • PD-1 and PD-L1 inhibitors (5)
  • Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors (1)
  • Pulmonary arterial hypertension (1)
  • Rising of Orphan Drug Development (2)
  • Snippets (96)
  • Specialized Reports (15)
  • The Business Cocktail (85)
  • Uncategorized (61)
  • Venous Thromboembolism (3)

Archives

  • February 2019 (11)
  • January 2019 (18)
  • December 2018 (19)
  • November 2018 (26)
  • October 2018 (21)
  • September 2018 (20)
  • August 2018 (26)
  • July 2018 (13)
  • June 2018 (5)
  • May 2018 (8)
  • April 2018 (6)
  • March 2018 (14)
  • February 2018 (11)
  • January 2018 (15)
  • December 2017 (8)
  • November 2017 (13)
  • October 2017 (8)
  • September 2017 (14)
  • August 2017 (13)
  • July 2017 (9)
  • June 2017 (14)
  • May 2017 (20)
  • April 2017 (19)
  • March 2017 (24)
  • February 2017 (21)
  • January 2017 (23)
  • December 2016 (22)
  • November 2016 (23)
  • October 2016 (17)
  • September 2016 (21)
  • August 2016 (17)
  • May 2016 (4)
  • March 2016 (8)
  • February 2016 (3)
  • January 2016 (7)
  • November 2015 (1)
  • October 2015 (1)
  • September 2015 (2)
  • August 2015 (2)
  • July 2015 (8)
  • June 2015 (4)
  • May 2015 (1)
  • April 2015 (5)
  • March 2015 (6)
  • February 2015 (2)
  • January 2015 (5)
  • December 2014 (17)
  • November 2014 (2)
  • September 2014 (1)
  • August 2014 (7)
  • July 2014 (7)
delveinsight


Quick Links

  • About
  • Capabilities & Solutions
  • Report Store
  • Media
  • Career
  • Contact Us

Contact Us

Phone

India: +91-11-45689769, +91-9650213330

Email

info@delveinsight.com

Address

New Delhi-110075, India

Address

304 S. Jones Blvd #2432, Las Vegas NV 89107

Phone

Outside India: +1(919)321-6187

Latest Tweets

Tweets by @DelveInsight

Copyright © 2019 Delveinsight.

  • Sitemap
  • Terms & Conditions
  • Privacy policy